Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with stage 2 hypertension within protocol limits at randomization
Patients with type 2 diabetes mellitus with HgA1c less than or equal to 9%
Patients with newly diagnosed hypertension or patients who have not received antihypertensive therapy for at least 4 weeks prior to screening
You may not be if
Patients taking 4 or more antihypertensive medications at screening visit
Patients with uncontrolled BP (\> 140/90 mmHg) while taking 3 or more antihypertensives at their maximum approved doses
Type 2 diabetes mellitus requiring insulin treatment
Patients with HgA1c \> 9%
Patients with known gout
Known history of cancer within the past 5 years
Patients who are pregnant or nursing mothers
Patients who have participated in an investigational clinical trial within the 30 days prior to screening.
Clareo Health | Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
